Search

Displaying results 3211 - 3220 of 10000 in total
  1. Drug

    INM005

    go.drugbank.com/drugs/DB16499
    Investigational

    INM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984).

  2. Drug

    Benzgalantamine

    go.drugbank.com/drugs/DB19353
    ApprovedInvestigational

    [L51564] Benzgalantamine was approved by the FDA in July 2024 for the treatment of mild-to-moderate dementia in Alzheimer's patients.[L51534,L51564] … [A264454] As a prodrug, benzagalantamine remains inert as it passes through the stomach, thereby avoiding many of the gastrointestinal effects associated with peripheral cholinesterase inhibition.

    Synonyms: 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, benzoate (ester), (4as,6r,8as)-
  3. Drug

    Dimazole

    go.drugbank.com/drugs/DB13858
    ApprovedWithdrawn

    Dimazole (diamthazole) is an antifungal. It was withdrawn in Franch in 1972 due to neuropsychiatric reactions.

  4. Drug

    Panitumumab

    go.drugbank.com/drugs/DB01269
    ApprovedInvestigational

    This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.[L17663]

  5. Drug

    L-arginine

    go.drugbank.com/drugs/DB17289
    ApprovedInvestigationalNutraceutical

    Mixtures: Clinimix E, Clinimix E
  6. Drug

    Dehydroascorbic acid

    go.drugbank.com/drugs/DB08830
    Experimental

    Dehydroascorbic acid as well as ascorbic acid are both termed Vitamin C, but the latter is the main form found in humans. … In the body, both dehydroascorbic acid and ascorbic acid have similar biological activity as antivirals but dehydroascorbic acid also has neuroprotective effects.

  7. Drug

    Opaganib

    go.drugbank.com/drugs/DB12764
    Investigational

    [L27436] This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in oncology, inflammation, the gastrointestinal system, and COVID-19. … Opaganib, also known as ABC294640, is a selective [sphingosine kinase-2 (SK2)](https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered.

  8. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875] … autoimmune hemolysis that are often observed in CHAPLE disease.

  9. Drug

    Iron Dextran

    go.drugbank.com/drugs/DB00893
    ApprovedInvestigationalVet approved

    Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity. … Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.